QRG Capital Management Inc. Purchases 1,046 Shares of DexCom, Inc. (NASDAQ:DXCM)

QRG Capital Management Inc. lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 10.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,896 shares of the medical device company’s stock after acquiring an additional 1,046 shares during the period. QRG Capital Management Inc.’s holdings in DexCom were worth $1,511,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in DXCM. DSM Capital Partners LLC bought a new stake in shares of DexCom during the fourth quarter worth $28,000. Valley National Advisers Inc. increased its position in shares of DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after acquiring an additional 103 shares in the last quarter. Riverview Trust Co acquired a new position in DexCom during the first quarter worth $32,000. MV Capital Management Inc. boosted its holdings in DexCom by 99.3% during the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after purchasing an additional 138 shares during the last quarter. Finally, Smithfield Trust Co boosted its holdings in DexCom by 103.1% during the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock worth $40,000 after purchasing an additional 165 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on DXCM shares. Redburn Atlantic started coverage on shares of DexCom in a report on Thursday, May 30th. They set a “neutral” rating and a $130.00 target price for the company. Morgan Stanley cut their price target on shares of DexCom from $132.00 to $120.00 and set an “equal weight” rating for the company in a research note on Monday. Stifel Nicolaus cut their price target on shares of DexCom from $145.00 to $132.00 and set a “buy” rating for the company in a research note on Friday, July 12th. UBS Group increased their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Finally, Raymond James increased their price target on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research note on Friday, April 26th. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $139.33.

DexCom Price Performance

DXCM stock traded down $0.85 during mid-day trading on Wednesday, hitting $115.21. The stock had a trading volume of 381,574 shares, compared to its average volume of 2,856,161. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08. DexCom, Inc. has a 52 week low of $74.75 and a 52 week high of $142.00. The firm has a market capitalization of $45.82 billion, a P/E ratio of 74.88, a P/E/G ratio of 2.76 and a beta of 1.16. The firm has a fifty day simple moving average of $118.92 and a 200 day simple moving average of $124.86.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.05. The company had revenue of $921.00 million for the quarter, compared to analyst estimates of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. As a group, research analysts forecast that DexCom, Inc. will post 1.78 EPS for the current year.

Insider Activity at DexCom

In other DexCom news, Director Bridgette P. Heller sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $113.55, for a total value of $113,550.00. Following the completion of the transaction, the director now directly owns 25,349 shares in the company, valued at approximately $2,878,378.95. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, Director Bridgette P. Heller sold 1,000 shares of the stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $113.55, for a total value of $113,550.00. Following the completion of the sale, the director now owns 25,349 shares of the company’s stock, valued at $2,878,378.95. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Jereme M. Sylvain sold 745 shares of DexCom stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $115.05, for a total value of $85,712.25. Following the completion of the transaction, the chief financial officer now directly owns 84,948 shares in the company, valued at $9,773,267.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 4,112 shares of company stock valued at $480,861. 0.30% of the stock is owned by insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.